Clinical Trials Directory

Trials / Completed

CompletedNCT02065999

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Kirby Institute · Other Government
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in the era of directly acting antiviral drugs for hepatitis C therapy.

Detailed description

1. To analyse for resistance-associated HCV variants in DAA-naïve HCV patients using population and ultra-deep pyrosequencing (UDPS). Resistance associated variants will be analysed by qualitative and quantitative methods both pre-treatment and on-treatment. 2. To determine whether in the absence of drug pressure there is variation in the prevalence of naturally occurring resistance associated variants. 3. To correlate the presence and frequency of baseline resistance-associated variants with the response to therapy with DAA-based triple therapy regimens for HCV. 4. To identify predictors of emergent DAA resistance and treatment failure during therapy with DAA-based combination strategies, including virological, clinical and immunological factors. 5. To characterize the natural history of HCV resistance associated variants that are selected during antiviral therapy after the withdrawal of treatment. 6. To establish a cohort of DAA-treatment failure patients suitable for re-treatment studies. 7. To establish a tissue repository of serum and PBMCs from well-characterized patients treated with DAA-based triple therapy to allow future examination of the role of other variables that may potentially impact on the outcomes of DAA based therapy and development of RAVs.

Conditions

Timeline

Start date
2012-11-01
Primary completion
2022-06-01
Completion
2022-06-01
First posted
2014-02-19
Last updated
2024-03-06

Locations

2 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT02065999. Inclusion in this directory is not an endorsement.